Cumberland Pharmaceuticals (CPIX) to Release Quarterly Earnings on Tuesday

Cumberland Pharmaceuticals (NASDAQ:CPIX) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, May 7th. Parties that are interested in registering for the company’s conference call can do so using this link.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings data on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. The firm had revenue of $9.35 million for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 6.84% and a negative net margin of 15.87%.

Cumberland Pharmaceuticals Trading Up 4.6 %

NASDAQ CPIX opened at $1.58 on Friday. Cumberland Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $2.36. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.11 and a current ratio of 1.28. The stock’s 50 day moving average price is $1.78 and its two-hundred day moving average price is $1.86.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Cumberland Pharmaceuticals in a report on Thursday. They set a “hold” rating for the company.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.